Obermatt

Medline

NSQ:MDLN · US58507V1070
Health Care Equipment & SuppliesX-Large

360

33
EV / EBIT35
Price / Owner Earnings41
Owner Earnings Yield61
Dividend Yield1
Price/Sales89
EV / Gross Profit51
Price/Book62
Return on Capital55
Cash Return on Capital58
Return on Equity51
EBIT Margin41
Gross Profitability34
Cash Conversion36
Accruals27
Owner Earnings Margin46
Sales growth52
Profit Growth96
Long-Term EPS Growth39
Owner Earnings Growth31
Reinvestment43
Price momentum31
Debt load47
Refinancing94
Debt Payback23
Liquidity50
Analyst ratings55
Opinion Changes52
Price Target Upside79
Market mood7
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Medline clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHealth Care Equipment & Supplies
SizeX-Large
TypePublic Company
ExchangeNASDAQGS
Founded2024
ISINUS58507V1070
Last UpdateApr 2, 2026
Themes
Health DiagnosticsSurgeryOrthopaedics

Description

Medline Inc. (‘Medline’), together with its subsidiaries, provides medical-surgical (‘med-surg’) products and supply chain solutions. Medline delivers mission-critical products used daily across the full range of care settings, from hospitals and su…

Analysis

Middle-of-the-road

Medline Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is fair. The owner-earnings multiple stands at 20.8×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 7% a year, against analyst forecasts of 5%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is stretched. The company scores 10/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
44
2026

All-time high

94

Mar 2026

All-time low

44

Jun 2026

Average rank

69

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
89
Price/Earnings
45
Price/Book
62
Dividend Yield
1
Value (overall)
65

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Medline with its peers
MiMedx
NAQ:MDXG
77
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Kimberly-Clark
NSQ:KMB
32
CountryUSA
IndustryHousehold Products
SizeLarge
Full Stock Analysis →
South Bow
TOR:SOBO
22
CountryCanada
IndustryOil, Gas & Consumable Fuels
SizeMedium
Full Stock Analysis →
Solstice Advanced Materials
NSQ:SOLS
8
CountryUSA
IndustryChemicals
SizeLarge
Full Stock Analysis →
Nutex Health
NAQ:NUTX
100
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Karat Packaging
NSQ:KRT
94
CountryUSA
IndustryTrading Companies & Distributors
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →